{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"1.7","upperLimit":"2.5","value":"2.1"},{"groupId":"OG001","lowerLimit":"2.6","upperLimit":"3.8","value":"3.2"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"21"},{"groupId":"OG001","value":"13"}],"units":"Participants"}],"description":"The length of time during and after the treatment a participant lives without disease progression. Time to progression functions estimated using the Kaplan-Meier method. Participants who drop out of the study included in the time to event data analysis as \"censored data\".","dispersionType":"95% Confidence Interval","groups":[{"description":"Abraxane 220 mg/m\\^2 intravenously on Day 1 of 21 day cycle.","id":"OG000","title":"CIMP-high Colorectal Cancer"},{"description":"Abraxane 220 mg/m\\^2 intravenously on Day 1 of 21 day cycle.","id":"OG001","title":"Small Bowel Adenocarcinoma"}],"paramType":"MEDIAN","populationDescription":"For progression-free survival, the intent-to-treat analysis performed using all available participants.","reportingStatus":"POSTED","timeFrame":"Assessed at first cycle (21 days), up to 12 months","title":"Progression-Free Survival (PFS)","type":"SECONDARY","unitOfMeasure":"Months"}